newsfilter
← Latest News
Business Wire·

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

Study met primary endpoint, showing a statistically significant increase in the percentage of participants achieving EASI-75 versus placebo at Week 16, for the potentially first-in-class trispecific antibody Pfizer